Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria

Summary

This study is being conducted to evaluate the efficacy and safety of povorcitinib in adults with CSU that is inadequately controlled using SOC treatments.

Timeline

Start

2023-07-31

Primary completion

2025-02-28

Completion

2025-10-09

Outcome

Met primary endpoint

registry analysis (superiority test); Placebo vs Povorcitinib 75 mg QD; p = 0.0470; least squares mean difference -6.01 (95% CI -11.94 to -0.08) NCT05936567 ↗

Drugs

Indications